The RADAR study: Week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Bedimo, Roger J ^a   Drechsler, Henning ^a   Jain, Mamta ^a   Cutrell, James ^b   Zhang, Song ^a   Li, Xilong ^a   Farukhi, Irfan ^b   Castanon, Rosinda ^b   Tebas, Pablo ^c   Maalouf, Naim M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LIPID; RALTEGRAVIR; UNCLASSIFIED DRUG; VIRUS RNA; 2 PYRROLIDONE DERIVATIVE; ADENINE; DARUNAVIR; DEOXYCYTIDINE; EMTRICITABINE; PHOSPHONIC ACID DERIVATIVE; SULFONAMIDE; TENOFOVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BODY FAT; BONE; BONE DENSITY; BONE HEALTH; BONE TURNOVER; CD4+ T LYMPHOCYTE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERTRANSAMINASEMIA; INTENTION TO TREAT ANALYSIS; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY;

ADENINE; ADULT; BONE DENSITY; DARUNAVIR; DEOXYCYTIDINE; EMTRICITABINE; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; ORGANOPHOSPHONATES; PYRROLIDINONES; RALTEGRAVIR POTASSIUM; SULFONAMIDES; TENOFOVIR;

EID: 84937484295     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106221     Document Type: Article

References (25)

1. Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P (2012) Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS 26: 825-831.
2. D:A:D Study Group, Sabin CA, Worm SW, Weber R, Reiss P, et al. (2008) Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371: 1417-1426.
3. SMART/INSIGHT Study Group, D:A:D Study Group (2008) Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 22: F17-24.
4. Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, et al. (2009) Abacavirlamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 361: 2230-2240.
5. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, et al. (2008) Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 358: 2095-2106. (Pubitemid 351679596)
6. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, et al. (2009) Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 374: 796-806.
7. Reynes J, Trinh R, Pulido F, Soto-Malave R, Gathe J, et al. (2013) Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviralnaive subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retroviruses 29: 256-265.
8. Reynes J, Lawal A, Pulido F, Soto-Malave R, Gathe J, et al. (2011) Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/emtricitabine in antiretroviral-naive subjects: the progress study, 48-week results. HIV Clin Trials 12: 255-267.
9. Kozal MJ, Lupo S, DeJesus E, Molina JM, McDonald C, et al. (2012) A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naive HIV-infected patients: SPARTAN study results. HIV Clin Trials 13: 119-130.
10. Taiwo B, Zheng L, Gallien S, Matining RM, Kuritzkes DR, et al. (2011) Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). Aids 25: 2113-2122.
11. Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, et al. (2008) Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. Aids 22: 395-402.
12. Brown TT, Qaqish RB (2006) Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. Aids 20: 2165-2174. (Pubitemid 44684707)
13. Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, et al. (2000) Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. Aids 14: F63-67. (Pubitemid 30182458)
14. McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, et al. (2005) CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study. Clin Infect Dis 41: 1662-1670. (Pubitemid 41691607)
15. Ofotokun I, Weitzmann N, Vunnava A, Sheth A, Villinger F, et al. (2011) HAART-induced Immune Reconstitution: A Driving Force Behind Bone Resorption in HIV/AIDS. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA.
16. van Vonderen MG, Mallon P, Murray B, Doran P, van Agtmael MA, et al. (2011) Changes in Bone Biomarkers in ARV-naïve HIV+ Men Randomized to NVP/LPV/r or AZT/3TC/LPV/r Help Explain Limited Loss of Bone Mineral Density over the First 12 Months after ART Initiation. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA.
17. Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, et al. (2010) Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 51: 963-972.
18. Martin A, Bloch M, Amin J, Baker D, Cooper DA, et al. (2009) Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis 49: 1591-1601.
19. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, et al. (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292: 191-201. (Pubitemid 38917996)
20. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, et al. (2011) Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202. J Infect Dis 203: 1791-1801.
21. Food and Drug Administration (2002) FDA Guidance for Industry. Antiretroviral drugs using plasma HIV RNA measurements-clinical considerations for accelerated and traditional approval, prepared by the Division of Antiviral Drug Products: Office of Drug Evaluation IV in the Centre for Drug Evaluation and Research (CDER), Appendix B, October 2002.
22. Tungsiripat M, Kitch D, Glesby MJ, Gupta SK, Mellors JW, et al. (2010) A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS 24: 1781-1784.
23. Cotter AG, Vrouenraets SM, Brady JJ, Wit FW, Fux CA, et al. (2013) Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study. J Clin Endocrinol Metab 98: 1659-1666.
24. Foca E, Motta D, Borderi M, Gotti D, Albini L, et al. (2012) Prospective evaluation of bone markers, parathormone and 1,25-(OH)(2) vitamin D in HIVpositive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz. BMC Infect Dis 12: 38.
25. Yin MT, Shane E (2006) Low bone-mineral density in patients with HIV: pathogenesis and clinical significance. Curr Opin Endocrinol Diabetes 13: 497-502. (Pubitemid 44691254)